244 related articles for article (PubMed ID: 30327255)
1. Drug Policy in the Russian Federation.
Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
[TBL] [Abstract][Full Text] [Related]
2. Drug Policy in Greece.
Yfantopoulos JN; Chantzaras A
Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
[TBL] [Abstract][Full Text] [Related]
3. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
4. Drug Policy in Latvia.
Silins J; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
[TBL] [Abstract][Full Text] [Related]
5. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
7. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
8. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
9. Drug Policy in Estonia.
Mägi K; Lepaste M; Szkultecka-Dębek M
Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
[TBL] [Abstract][Full Text] [Related]
10. Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation.
Prasolov AV; Kolbin AS; Balykina YE
Value Health Reg Issues; 2018 Sep; 16():39-45. PubMed ID: 29933241
[TBL] [Abstract][Full Text] [Related]
11. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Hu J; Mossialos E
Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
[TBL] [Abstract][Full Text] [Related]
13. CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE.
Kani C; Kourafalos V; Litsa P
Int J Technol Assess Health Care; 2017 Jan; 33(3):396-401. PubMed ID: 28756795
[TBL] [Abstract][Full Text] [Related]
14. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
15. Drug Policy in Hungary.
Inotai A; Csanádi M; Harsányi A; Németh B
Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
[TBL] [Abstract][Full Text] [Related]
16. New Drug Reimbursement and Pricing Policy in Taiwan.
Chen GT; Chang SC; Chang CJ
Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
[TBL] [Abstract][Full Text] [Related]
17. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
18. The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.
Wasir R; Irawati S; Makady A; Postma M; Goettsch W; Feenstra T; Buskens E
PLoS One; 2019; 14(11):e0225626. PubMed ID: 31774854
[TBL] [Abstract][Full Text] [Related]
19. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
Beletsi A; Koutrafouri V; Karampli E; Pavi E
Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
Drummond M; Jönsson B; Rutten F; Stargardt T
Eur J Health Econ; 2011 Jun; 12(3):263-71. PubMed ID: 20803050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
